I-MAB ( (IMAB) ) just unveiled an update.
In April 2025, I-Mab announced the completion of its divestiture of China operations in 2024, positioning itself for accelerated growth with a focus on precision immuno-oncology therapeutics. The company is advancing three clinical programs, led by Givastomig, a potential best-in-class therapeutic for gastric cancer. I-Mab’s lean and focused strategy, along with its capital-efficient operating model, is expected to support its clinical trial operations in the U.S. and extend its cash runway into 2027. The company’s strategic realignment and focus on innovative cancer treatments are anticipated to enhance its industry positioning and offer significant implications for stakeholders.
More about I-MAB
I-Mab is a U.S.-based biotechnology company focused on precision immuno-oncology therapeutics. The company is engaged in developing a pipeline of innovative drug candidates, including bispecific antibodies and monoclonal antibodies, targeting various cancers such as gastric cancer and metastatic non-small cell lung cancer.
YTD Price Performance: -19.78%
Average Trading Volume: 314,158
Technical Sentiment Signal: Strong Buy
Current Market Cap: $56.23M
See more data about IMAB stock on TipRanks’ Stock Analysis page.